Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD63m

    Last close

    USD0.68

    ▲ 0.10 (16.35%)

    Creotech Instruments

    MCap

    PLN346m

    Last close

    PLN174.00

    ▲ 23.50 (15.61%)

    Creo Medical

    MCap

    GBP80m

    Last close

    GBP0.19

    ▲ 2.25 (13.24%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

IRLAB Therapeutics AB: Edison Open House Healthcare 2022

IRLAB Therapeutics AB: Edison Open House Healthcare 2022

IRLAB Therapeutics — 7 videos in collection

More on this equity

IRLAB Therapeutics AB is dedicated to the discovery and development of new drugs for treatment of Parkinson’s disease and other life-altering diseases that affect the central nervous system (CNS). IRLAB strive to transform the everyday life for patients who lack effective treatment options.

• Tell us about the company, its key assets and the particular areas of focus.
• What is IRLAB’s proprietary ISP platform, which leads to these discoveries?
• Tell us about some of the company’s assets.
• Tell us more about the successful deal to out-license your lead asset Mesdopetam to Ipsen in summer 2021.
• At what stage is pirepemat, your next most advanced Parkinson’s asset, in its development timeline?
• Are the other developments in your pipeline also assets focusing on the neglected effects of Parkinson’s disease?
• Which milestones should investors look out for in the coming year?

< Previous
Next >

You may also be interested in these:

Healthcare

IRLAB Therapeutics – executive interview

Healthcare

IRLAB Therapeutics – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free